The Triple Bottom Line is anchored in the company's Articles of Association (bylaws) and the Novo Nordisk Way as the way we do business. It is applied to ensure that business decisions balance financial, social and environmental considerations, always keeping in mind the best interests of the patients we serve.
Novo Nordisk’s ambition is to be a sustainable business. By this we mean:
Since 2004, we have published one integrated annual report that accounts for our financial, social and environmental performance. Find more information about our performance across the Triple Bottom Line on these pages.
Together with partners, we work to improve access to diabetes care worldwide. The same goes for access to treatment for obesity, haemophilia and growth disorder.
Adhering to high business ethics standards and respecting people and their rights is the foundation of a responsible business.
By providing a safe, diverse and engaging work environment, we hope to attract and develop the best people in our organisation.
Our ambition to be a sustainable business entails that we work on cross-cutting issues and account for performance in several ways.